Christopher B. Granger, MD, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Boehringer Ingelheim(SIGNIFICANT), Pfizer(SIGNIFICANT), AstraZeneca(SIGNIFICANT), Bristol Myers Squibb(SIGNIFICANT), Boston Scientific(MODEST), AbbVie, Inc.(MODEST), Bayer(MODEST), NIH(MODEST), Medscape(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Medtronic Inc(SIGNIFICANT), Espero(MODEST), Novo Nordisk Inc.(SIGNIFICANT), Roche(MODEST), Janssen Pharmaceuticals, Inc(SIGNIFICANT), Janssen(SIGNIFICANT), Correvio(SIGNIFICANT), CeleCor(SIGNIFICANT), Rhoshan(MODEST) RESEARCH/RESEARCH GRANTS: Astra Zeneca(SIGNIFICANT), GlaxoSmithKline(SIGNIFICANT), Medtronic Foundation(SIGNIFICANT), Boehringer Ingelheim(SIGNIFICANT), Bristol Myers Squibb(SIGNIFICANT), Pfizer(SIGNIFICANT), Janssen Pharmaceuticals(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), FDA(SIGNIFICANT), Akros(SIGNIFICANT), Apple(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT), Novartis Corporation(SIGNIFICANT)

View Full Disclosure